A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151).
Lu Si,Xiaoshi Zhang,Yongqian Shu,Hongming Pan,Di Wu,Jiwei Liu,Fang Lou,Lili Mao,Xuan Wang,Xizhi Wen,Yanhong Gu,Lingjun Zhu,Shijie Lan,Xin Cai,Scott J. Diede,Yu Zhou,Jun Ge,Jianfeng Li,Haiyan Wu,Jun Guo +19 more
Reads0
Chats0
TLDR
Pembrolizumab was well tolerated and provided clinically meaningful antitumor activity as second-line therapy in Chinese patients with advanced melanoma and two deaths occurred that were unrelated to treatment.About:
This article is published in Translational Oncology.The article was published on 2019-06-01 and is currently open access. It has received 80 citations till now. The article focuses on the topics: Mucosal melanoma & Pembrolizumab.read more
Citations
More filters
Journal ArticleDOI
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Lin Shen,Jun Guo,Qingyuan Zhang,Hongming Pan,Ying Yuan,Yuxian Bai,Tianshu Liu,Qing Zhou,Jun Zhao,Yongqian Shu,Xiaoming Huang,Siyang Wang,Jie Wang,Ai-Ping Zhou,Dingwei Ye,Ting Sun,Yujuan Gao,Silu Yang,Zoubai Wang,Jian Li,Yi-Long Wu +20 more
TL;DR: Tislelizumab was generally well tolerated among Chinese patients andAntitumor activity was observed in patients with multiple solid tumors, including nasopharyngeal carcinoma cohort.
Journal ArticleDOI
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients.
Yasuhiro Nakamura,Kenjiro Namikawa,Koji Yoshino,S. Yoshikawa,Hiroshi Uchi,K. Goto,Satoshi Fukushima,Yukiko Kiniwa,Tatsuya Takenouchi,Hisashi Uhara,Toru Kawai,Naohito Hatta,Takeru Funakoshi,Yukiko Teramoto,Atsushi Otsuka,Haruki Doi,Dai Ogata,Shigeto Matsushita,Taiki Isei,Toshihiko Hayashi,Yoshitsugu Shibayama,Naoya Yamazaki +21 more
TL;DR: In this article, the anti-programmed cell death 1 (anti-PD-1) antibody was used as first-line therapy for Acral melanoma (AM) patients.
Journal ArticleDOI
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials.
Bin Zhao,Hong Zhao,Jiaxin Zhao +2 more
TL;DR: The objective response rates (ORRs), progression-free survival (PFS), and overall survival (OS) of PD-1/PD-L1 blockade monotherapy have not been systematically evaluated and vary significantly across cancer types and PD-L 1 expression.
Journal ArticleDOI
Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
TL;DR: In this paper, the authors comprehensively review current knowledge on the clinicopathological characteristics and mutational landscapes of acral and mucosal melanomas, as well as providing an overview of current therapies for patients with these aggressive melanoma subtypes, focusing on available immunotherapeutic interventions.
Journal ArticleDOI
Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
TL;DR: This study aimed to assess the incidence of immune‐related adverse events associated with ICIs and to have a better understanding of irAEs and to be able to manage them systematically.
References
More filters
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
TL;DR: A marked increase in the use of international datasets for more highly evidenced-based changes in staging, and the enhanced use of nonanatomic prognostic factors in defining the stage grouping are notable.
Journal ArticleDOI
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert,Luc Thomas,Igor Bondarenko,Steven J. O'Day,Jeffrey S. Weber,Claus Garbe,Céleste Lebbé,Jean Francois Baurain,Alessandro Testori,Jean-Jacques Grob,Neville Davidson,Jon M. Richards,Michele Maio,Axel Hauschild,Wilson H. Miller,Pere Gascón,Michal Lotem,Kaan Harmankaya,Ramy Ibrahim,Stephen Francis,Tai-Tsang Chen,R. Humphrey,Axel Hoos,Jedd D. Wolchok +23 more
TL;DR: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma.
Journal ArticleDOI
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid,Caroline Robert,Adil Daud,F. Stephen Hodi,Wen-Jen Hwu,Richard F. Kefford,Jedd D. Wolchok,Peter Hersey,Richard W. Joseph,Jeffrey S. Weber,Roxana S. Dronca,Tara C. Gangadhar,Amita Patnaik,Hassane M. Zarour,Anthony M. Joshua,Kevin Gergich,Jeroen Elassaiss-Schaap,Alain Algazi,Christine Mateus,Peter D. Boasberg,Paul C. Tumeh,Bartosz Chmielowski,Scot Ebbinghaus,Xiaoyun Nicole Li,S. Peter Kang,Antoni Ribas +25 more
TL;DR: In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects.
Journal ArticleDOI
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert,Boguslawa Karaszewska,Jacob Schachter,Piotr Rutkowski,Andrzej Mackiewicz,Daniil Stroiakovski,Michael Lichinitser,Reinhard Dummer,Florent Grange,Laurent Mortier,Vanna Chiarion-Sileni,Kamil Drucis,Ivana Krajsová,Axel Hauschild,Paul Lorigan,Pascal Wolter,Georgina V. Long,Keith T. Flaherty,Paul Nathan,Antoni Ribas,Antoni Ribas,Anne-Marie Martin,Peng Sun,Wendy A. Crist,Jeff Legos,Stephen D. Rubin,Shonda M Little,Dirk Schadendorf +27 more
TL;DR: Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity.
Related Papers (5)
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward,Nicholas K. Hayward,James S. Wilmott,Nicola Waddell,Nicola Waddell,Peter Johansson,Matthew A. Field,Katia Nones,Katia Nones,Ann-Marie Patch,Ann-Marie Patch,Hojabr Kakavand,Ludmil B. Alexandrov,Hazel Burke,Valerie Jakrot,Stephen H. Kazakoff,Stephen H. Kazakoff,Oliver Holmes,Oliver Holmes,Conrad Leonard,Conrad Leonard,Radhakrishnan Sabarinathan,Loris Mularoni,Scott Wood,Scott Wood,Qinying Xu,Qinying Xu,Nick Waddell,Varsha Tembe,Gulietta M. Pupo,Ricardo De Paoli-Iseppi,Ricardo E. Vilain,Ping Shang,Loretta Lau,Rebecca A. Dagg,Sarah-Jane Schramm,Antonia L. Pritchard,Ken Dutton-Regester,Felicity Newell,Anna Fitzgerald,Catherine A. Shang,Sean M. Grimmond,Hilda A. Pickett,Jean Y. Yang,Jonathan R. Stretch,Andreas Behren,Richard F. Kefford,Richard F. Kefford,Peter Hersey,Georgina V. Long,Georgina V. Long,Jonathan Cebon,Mark Shackleton,Andrew J. Spillane,Robyn P. M. Saw,Nuria Lopez-Bigas,Nuria Lopez-Bigas,John V. Pearson,John V. Pearson,John F. Thompson,Richard A. Scolyer,Richard A. Scolyer,Graham J. Mann +62 more
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P. D'Angelo,James Larkin,Jeffrey A. Sosman,Céleste Lebbé,Benjamin Brady,Bart Neyns,Henrik Schmidt,Jessica C. Hassel,F. Stephen Hodi,Paul Lorigan,Kerry J. Savage,Wilson H. Miller,Peter Mohr,Ivan Marquez-Rodas,Julie Charles,Martin Kaatz,Mario Sznol,Jeffrey S. Weber,Alexander N. Shoushtari,Mary Ruisi,Joel Jiang,Jedd D. Wolchok +21 more
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert,Antoni Ribas,Jacob Schachter,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Teresa M. Petrella,Omid Hamid,Shu Chih Su,Clemens Krepler,Nageatte Ibrahim,Georgina V. Long +19 more
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter,Antoni Ribas,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Teresa M. Petrella,Omid Hamid,Honghong Zhou,Scot Ebbinghaus,Nageatte Ibrahim,Caroline Robert +19 more